Combination of chidamide-mediated epigenetic modulation with immunotherapy: Boosting tumor immunogenicity and response to PD-1/PD-L1 blockade

K Tu, Y Yu, Y Wang, T Yang, Q Hu, X Qin… - … applied materials & …, 2021 - ACS Publications
Improving tumor immunogenicity is critical for increasing the responsiveness of triple-
negative breast cancer (TNBC) to anti-PD-(L) 1 treatment. Here, we verified that chidamide …
被引用次数：43 相关文章
[PDF] google.com

[PDF][PDF] Combination of chidamide-mediated epigenetic modulation with immunotherapy: Boosting tumor immunogenicity and response to PD-1/PD-L1 blockade

K Tu, Y Yu, Y Wang, T Yang, Q Hu, X Qin… - … applied materials & …, 2021 - drive.google.com
Improving tumor immunogenicity is critical for increasing the responsiveness of triple-
negative breast cancer (TNBC) to anti-PD-(L) 1 treatment. Here, we verified that chidamide …

Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade.

K Tu, Y Yu, Y Wang, T Yang, Q Hu, X Qin… - … Applied Materials & …, 2021 - europepmc.org
Improving tumor immunogenicity is critical for increasing the responsiveness of triple-
negative breast cancer (TNBC) to anti-PD-(L) 1 treatment. Here, we verified that chidamide …

Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade

K Tu, Y Yu, Y Wang, T Yang, Q Hu… - … applied materials & …, 2021 - pubmed.ncbi.nlm.nih.gov
Improving tumor immunogenicity is critical for increasing the responsiveness of triple-
negative breast cancer (TNBC) to anti-PD-(L) 1 treatment. Here, we verified that chidamide …

[引用][C] Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade

K Tu, Y Yu, Y Wang, T Yang, Q Hu, X Qin, J Tu, C Yang… - 2021